AU6648898A - Treatment of autoimmune disease using tolerization in combination with methotrexate - Google Patents
Treatment of autoimmune disease using tolerization in combination with methotrexateInfo
- Publication number
- AU6648898A AU6648898A AU66488/98A AU6648898A AU6648898A AU 6648898 A AU6648898 A AU 6648898A AU 66488/98 A AU66488/98 A AU 66488/98A AU 6648898 A AU6648898 A AU 6648898A AU 6648898 A AU6648898 A AU 6648898A
- Authority
- AU
- Australia
- Prior art keywords
- methotrexate
- disease
- autoimmune
- antigen
- bystander
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
- B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
- B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
- B41J2/01—Ink jet
- B41J2/21—Ink jet for multi-colour printing
- B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0094—Colour printing
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0097—Printing on special media, e.g. labels, envelopes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3672297P | 1997-01-24 | 1997-01-24 | |
US60036722 | 1997-01-24 | ||
PCT/US1998/001648 WO1998032451A1 (fr) | 1997-01-24 | 1998-01-26 | Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6648898A true AU6648898A (en) | 1998-08-18 |
Family
ID=21890248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU66488/98A Abandoned AU6648898A (en) | 1997-01-24 | 1998-01-26 | Treatment of autoimmune disease using tolerization in combination with methotrexate |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0994717A4 (fr) |
JP (1) | JP2001511134A (fr) |
KR (1) | KR20000070460A (fr) |
AU (1) | AU6648898A (fr) |
BR (1) | BR9807112A (fr) |
CA (1) | CA2278152A1 (fr) |
HU (1) | HUP0001960A2 (fr) |
IL (1) | IL131025A0 (fr) |
NO (1) | NO993600L (fr) |
WO (1) | WO1998032451A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2314182T3 (es) | 2002-02-11 | 2009-03-16 | Antares Pharma, Inc. | Inyector intradermico. |
EP1850892B2 (fr) | 2005-01-24 | 2023-04-19 | Antares Pharma, Inc. | Injecteur a seringue preremplie assiste d'une aiguille |
GB0523576D0 (en) * | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
WO2007131025A1 (fr) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Injecteur à dosage réglable |
WO2007131013A1 (fr) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Injecteur de reconstitution à deux étages |
JP5731829B2 (ja) | 2008-03-10 | 2015-06-10 | アンタレス・ファーマ・インコーポレーテッド | 注射器安全装置 |
AU2009279719B2 (en) | 2008-08-05 | 2015-07-23 | Antares Pharma, Inc. | Multiple dosage injector |
JP5732039B2 (ja) | 2009-03-20 | 2015-06-10 | アンタレス・ファーマ・インコーポレーテッド | 危険有害性薬剤の注入システム |
WO2011159821A1 (fr) | 2010-06-16 | 2011-12-22 | Bruce Chandler May | Utilisation de la lévocétirizine et du montélukast dans le traitement de la grippe, du rhume et d'une inflammation |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
DK2822618T3 (da) | 2012-03-06 | 2024-01-22 | Antares Pharma Inc | Forfyldt nål med brudkraftfunktion |
EP4186545A1 (fr) | 2012-04-06 | 2023-05-31 | Antares Pharma, Inc. | Administration par injection par jet assistée par aiguille de compositions de testostérone |
US9364610B2 (en) | 2012-05-07 | 2016-06-14 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
EP4349383A2 (fr) | 2013-02-11 | 2024-04-10 | Antares Pharma, Inc. | Dispositif d'injection par jet assisté par aiguille ayant une force de déclenchement réduite |
JP6030803B2 (ja) | 2013-03-11 | 2016-11-24 | アンタレス・ファーマ・インコーポレーテッド | ピニオンシステムを有する用量注射器 |
WO2014165136A1 (fr) | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Seringues pré-remplies à volume constant et leurs trousses |
EP2969010B1 (fr) * | 2013-03-13 | 2017-10-11 | Inflammatory Response Research, Inc. | Utilisation de levocetirizine et de montelukast dans le traitement des maladies auto-immunes |
EP2969002B8 (fr) | 2013-03-13 | 2018-02-21 | Inflammatory Response Research, Inc. | Utilisation de levocetirizine et montelukast dans le traitement de blessure traumatique |
CN105263579B (zh) | 2013-03-13 | 2020-01-10 | 炎症反应研究公司 | 左西替利嗪和孟鲁司特在治疗血管炎中的用途 |
WO2016044095A1 (fr) | 2014-09-15 | 2016-03-24 | Inflammatory Response Research, Inc. | Lévocétirizine et montélukast dans le traitement de troubles médiés par une inflammation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE258065T1 (de) * | 1987-06-24 | 2004-02-15 | Brigham & Womens Hospital | Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen |
US5571500A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
US5571499A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
AU650065B2 (en) * | 1990-09-06 | 1994-06-09 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | Inhibitor of lymphocyte response and immune-related disease |
HU220357B (hu) * | 1992-02-28 | 2001-12-28 | Autoimmune Inc. | Eljárás és készítmények autoimmun betegségek kezelésére bystander antigén alkalmazásával |
WO1996040235A1 (fr) * | 1995-06-07 | 1996-12-19 | Nexstar Pharmaceuticals, Inc. | Procede d'utilisation de superantigenes pour cibler des sous-populations de lymphocytes t |
EP0834321B1 (fr) * | 1995-06-13 | 2003-05-02 | Nippon Meat Packers, Inc. | Medicament a administration par voie orale contre la polyarthrite rhumatoide et aliment fonctionnel |
-
1998
- 1998-01-26 BR BR9807112-2A patent/BR9807112A/pt not_active Application Discontinuation
- 1998-01-26 IL IL13102598A patent/IL131025A0/xx unknown
- 1998-01-26 WO PCT/US1998/001648 patent/WO1998032451A1/fr not_active Application Discontinuation
- 1998-01-26 JP JP53225298A patent/JP2001511134A/ja active Pending
- 1998-01-26 HU HU0001960A patent/HUP0001960A2/hu unknown
- 1998-01-26 EP EP98908452A patent/EP0994717A4/fr not_active Withdrawn
- 1998-01-26 AU AU66488/98A patent/AU6648898A/en not_active Abandoned
- 1998-01-26 KR KR1019997006698A patent/KR20000070460A/ko not_active Application Discontinuation
- 1998-01-26 CA CA002278152A patent/CA2278152A1/fr not_active Abandoned
-
1999
- 1999-07-23 NO NO993600A patent/NO993600L/no unknown
Also Published As
Publication number | Publication date |
---|---|
CA2278152A1 (fr) | 1998-07-30 |
IL131025A0 (en) | 2001-01-28 |
HUP0001960A2 (hu) | 2000-10-28 |
BR9807112A (pt) | 2001-09-18 |
NO993600L (no) | 1999-09-23 |
EP0994717A4 (fr) | 2000-07-26 |
WO1998032451A1 (fr) | 1998-07-30 |
JP2001511134A (ja) | 2001-08-07 |
EP0994717A1 (fr) | 2000-04-26 |
KR20000070460A (ko) | 2000-11-25 |
NO993600D0 (no) | 1999-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5935577A (en) | Treatment of autoimmune disease using tolerization in combination with methotrexate | |
AU720695B2 (en) | Bystander suppression of autoimmune diseases | |
US6645504B1 (en) | Bystander suppression of type I diabetes by oral administration of glucagon | |
AU6648898A (en) | Treatment of autoimmune disease using tolerization in combination with methotrexate | |
WO1998032451A9 (fr) | Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate | |
Miller et al. | Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. | |
EP1033998B1 (fr) | Suppression des modifications liees aux beta-amyloides dans la maladie d'alzheimer | |
AU9023791A (en) | Treatment of autoimmune diseases by oral administration of autoantigens | |
EP0506785A1 (fr) | Traitement ameliore de maladies auto-immunes par administration par aerosol d'auto-antigenes | |
AU695883B2 (en) | Treatment of autoimmune disease using oral tolerization and/or Th2-enhancing cytokines | |
AU686797B2 (en) | Treatment of autoimmune disease using oral tolerization and/or type I interferon | |
US20010007758A1 (en) | Treatment of multiple sclerosis using COP-1 and Th2-enhancing cytokines | |
US20040115217A1 (en) | Bystander suppression of autoimmune diseases | |
WO1994004121A1 (fr) | Suppression par un antigene tiers d'une maladie neurologique associee a un retrovirus | |
WO2008045488A2 (fr) | Traitement de l'inflammation, de la démyélinisation et de la perte neuronale/axonale | |
JP2001502306A (ja) | インシュリン依存性糖尿病の処置方法および組成物 | |
JP2003512435A (ja) | 予防及び治療方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |